Tesofensine produced weight loss significantly greater than placebo and was more effective than any currently approved obesity drug at the time. Astrup et al., The Lancet Additional Findings: The majority of weight loss came from visceral fat and abdominal adiposity Lean body mass was preserved , unlike with most appetite suppressants Participants reported reduced hunger and better diet adherence Tesofensine significantly improved waist circumference , lipid profiles, and fasting glucose These findings have led to continued interest in Tesofensines use for body recomposition not just for general weight loss, but for fat-specific reduction without muscle sacrifice
These changes correlate with weight loss magnitude, particularly reduction in visceral adiposity and neck circumference
SHIPPING & PACKAGING
The AFL has released a statement regarding the status of AOD-9604 AFL general counsel Andrew Dillon has made the following statement in relation to the status of AOD-9604: "When the Australian Crime Commission report was released in February this year, the report indicated AOD-9604 was not a banned substance
This appetite-neutral characteristic distinguishes AOD-9604 from medications like GLP-1 agonists (Semaglutide, Tirzepatide) that work primarily through appetite suppression
By prioritizing B12 intake, older adults can sustain their cognitive and physical health, leading to an improved quality of life